Page 2 - Nathan Kaiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rural ranchers hope to boost income with land leases to solar farms, but residents of neighboring housing developments don't want their views ruined.

Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

71% of Adult Patients in Phase 2 ZUMA-3 Study Achieved a Complete Response Following a Single Infusion of Tecartus -- - -- If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia -- Kite, a Gilead Company announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, ...

Trodelvy More than Doubled Overall Survival as Second-Line Treatment in New ASCENT Subgroup Analysis – Gilead Sciences, Inc. today announced new data from the Phase 3 ASCENT study evaluating Trodelvy ® in relapsed or refractory metastatic triple-negative breast cancer . In this subgroup analysis of brain metastases-negative patients who received only one line of prior systemic therapy in the metastatic setting in ...

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate as well as Kite’s chimeric antigen receptor T-cell … Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that...